Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $20.88 Consensus Price Target from Brokerages

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $20.88.

Several analysts recently commented on the stock. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, UBS Group boosted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.55% of the stock is owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several large investors have recently added to or reduced their stakes in the business. Stifel Financial Corp increased its stake in shares of Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after acquiring an additional 23,283 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after acquiring an additional 40,218 shares during the period. Sio Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $24,314,000. Two Sigma Advisers LP boosted its position in Teva Pharmaceutical Industries by 15.3% during the 3rd quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock worth $18,642,000 after purchasing an additional 137,000 shares during the period. Finally, TCW Group Inc. purchased a new position in Teva Pharmaceutical Industries in the third quarter valued at about $1,286,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $22.42 on Thursday. The company has a market cap of $25.40 billion, a P/E ratio of -26.38, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries has a one year low of $10.34 and a one year high of $22.50. The business has a fifty day moving average of $17.97 and a two-hundred day moving average of $17.60. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.